Legend Biotech (LEGN) Stock Price, News & Analysis

Company Overview

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma. Carvykti received U.S. Food and Drug Administration approval in February 2022, marking Legend Biotech’s transition into commercial operations. Beyond its flagship program, the company maintains a diversified pipeline, which includes additional hematologic and solid-tumor cell therapy candidates and next-generation platform technologies designed to enhance safety, scalability and patient access.

Founded in 2014 and backed by a robust collaboration agreement with Janssen, Legend Biotech completed its initial public offering on the Nasdaq in July 2019. The capital raise supported expansion of manufacturing capacity and accelerated global clinical development. Through its relationship with Janssen, Legend Biotech has laid the groundwork for regulatory filings and product launches across North America, Europe and Asia, leveraging Janssen’s established commercial network.

The company is led by Chief Executive Officer Dr. Ying Huang, whose leadership team combines expertise in cell therapy research, regulatory affairs and commercial execution. As Legend Biotech advances its clinical programs and scales its commercial infrastructure, it remains focused on expanding patient access to transformative therapies and exploring new indications in oncology.

Key Stats

• Today's Range: $27.36 to $29.88
• 50-Day Range: $16.80 to $28.51
• 52-Week Range: $16.24 to $45.30
• Volume: 3.47 million shs
• Average Volume: 2.77 million shs
• Market Capitalization: $5.36 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $58.31
• Consensus Rating: Moderate Buy

Legend Biotech Stock Analysis - MarketRank™

Legend Biotech scored higher than 67% of companies evaluated by MarketBeat, and ranked 224th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Legend Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 11 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Legend Biotech has a consensus price target of $58.31, representing about 101.3% upside from its current price of $28.96.

Amount of Analyst Coverage

Legend Biotech has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 441.94%

Earnings Growth

Earnings for Legend Biotech are expected to grow by 441.94% in the coming year, from $0.31 to $1.68 per share.

Price to Book Value per Share Ratio

Legend Biotech has a P/B Ratio of 5.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.39% of the float of Legend Biotech has been sold short.

Short Interest Ratio / Days to Cover

Legend Biotech has a short interest ratio ("days to cover") of 10.94, which indicates bearish sentiment.

Change versus previous month

Short interest in Legend Biotech has recently increased by 2.74%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Legend Biotech does not currently pay a dividend.

Dividend Growth

Legend Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.34

News Sentiment

Legend Biotech has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Legend Biotech this week, compared to 4 articles on an average week.

Search Interest

19 people have searched for LEGN on MarketBeat in the last 30 days. This is an increase of 171% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Legend Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Legend Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $87,139.00 in company stock.

Percentage Held by Insiders

0.02% of the stock of Legend Biotech is held by insiders.

Percentage Held by Institutions

70.89% of the stock of Legend Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LEGN Stock Analysis - Frequently Asked Questions

How have LEGN shares performed this year?

Legend Biotech's stock was trading at $21.74 at the start of the year. Since then, LEGN shares have increased by 33.2% and is now trading at $28.96.

How were Legend Biotech's earnings last quarter?

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) announced its earnings results on Wednesday, March, 11th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.18. Legend Biotech's revenue was up 64.2% compared to the same quarter last year.
Read the conference call transcript.

When did Legend Biotech IPO?

Legend Biotech (LEGN) raised $350 million in an initial public offering on Friday, June 5th 2020. The company issued 18,425,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies served as the underwriters for the IPO.

Who are Legend Biotech's major shareholders?

Legend Biotech's top institutional investors include Matthews International Capital Management LLC (0.50%), SG Americas Securities LLC (0.29%), Candriam S.C.A. (0.25%) and iA Global Asset Management Inc. (0.12%).
View institutional ownership trends.

How do I buy shares of Legend Biotech?

Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Legend Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Legend Biotech investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 3/11/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LEGN
• CIK: 1801198
• Web: www.legendbiotech.com
• Phone: 732-317-5050
• Fax: N/A
• Employees: 2,965
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Legend Biotech: $58.31
• High Price Target: $80.00
• Low Price Target: $21.00
• Potential Upside/Downside: +101.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 93.42
• P/E Growth: N/A
• Net Income: -$296.80 million
• Net Margins: -28.86%
• Pretax Margin: -27.47%
• Return on Equity: -21.93%
• Return on Assets: -13.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.96
• Quick Ratio: 1.91

Sales & Book Value

• Annual Sales: $1.03 billion
• Price / Sales: 5.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.43 per share
• Price / Book: 5.33

Miscellaneous

• Outstanding Shares: 184,960,000
• Free Float: 184,919,000
• Market Cap: $5.36 billion
• Optionable: Optionable
• Beta: 0.29